Kvols LK - Search Results

1

The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process.

Kvols LK, Brendtro KL; North American Neuroendocrine Tumor Society (NANETS). Kvols LK, et al. Pancreas. 2010 Aug;39(6):705-6. doi: 10.1097/MPA.0b013e3181eb7451. Pancreas. 2010. PMID: 20664469 No abstract available.

2

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.

Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK; North American Neuroendocrine Tumor Society (NANETS). Strosberg JR, et al. Among authors: kvols lk. Pancreas. 2010 Aug;39(6):799-800. doi: 10.1097/MPA.0b013e3181ebb56f. Pancreas. 2010. PMID: 20664477 Free PMC article.

3

Cytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage.

Henderson-Jackson EB, Nasir A, Chen DT, Nandyala P, Djeu J, Strosberg J, Kvols L, Coppola D. Henderson-Jackson EB, et al. Pancreas. 2013 Aug;42(6):967-70. doi: 10.1097/MPA.0b013e318293734b. Pancreas. 2013. PMID: 23770713 Free PMC article.

4

RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms.

Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, Henderson-Jackson EB, Hodul P, Bui MM, Nasir NA, Hakam A, Malafa MP, Yeatman TJ, Coppola D, Kvols LK. Nasir A, et al. Among authors: kvols lk. Pancreas. 2011 May;40(4):627-33. doi: 10.1097/MPA.0b013e3182152bda. Pancreas. 2011. PMID: 21499216 Free PMC article.

5

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A. Delpassand ES, et al. Among authors: kvols lk. Pancreas. 2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113. Pancreas. 2014. PMID: 24632546 Clinical Trial.

6

Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas.

Strosberg J, Gardner N, Kvols L. Strosberg J, et al. Pancreas. 2009 Apr;38(3):255-8. doi: 10.1097/MPA.0b013e3181917e4e. Pancreas. 2009. PMID: 19066493

7

Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels.

Nasir A, Gardner NM, Strosberg J, Ahmad N, Choi J, Malafa MP, Coppola D, Kwekkeboom DJ, Teunissen JJ, Kvols LK. Nasir A, et al. Among authors: kvols lk. Pancreas. 2008 Apr;36(3):309-13. doi: 10.1097/MPA.0b013e31815b321c. Pancreas. 2008. PMID: 18362846

8

Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience.

Ambe CM, Nguyen P, Centeno BA, Choi J, Strosberg J, Kvols L, Hodul P, Hoffe S, Malafa MP. Ambe CM, et al. Cancer Control. 2017 Oct-Dec;24(5):1073274817729076. doi: 10.1177/1073274817729076. Cancer Control. 2017. PMID: 28975822 Free PMC article.

9

Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.

Strosberg J, Gardner N, Kvols L. Strosberg J, et al. Neuroendocrinology. 2009;89(4):471-6. doi: 10.1159/000197899. Epub 2009 Jan 28. Neuroendocrinology. 2009. PMID: 19174605

10

A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours.

Strosberg JR, Kvols LK. Strosberg JR, et al. Among authors: kvols lk. Expert Opin Investig Drugs. 2007 Feb;16(2):219-24. doi: 10.1517/13543784.16.2.219. Expert Opin Investig Drugs. 2007. PMID: 17243941 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

212 results

Search Page